Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Fritz Leutmezer
Sign up to set email alerts
225
Publications
5,326
Citation Statements Received
6,047
Citation Statements Given
How they've been cited
6,180
310
4,965
51
How they cite others
5,968
491
5,501
55
Affiliations
Medical University of Vienna
,
University of Vienna
Publications
Order By: Most citations
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Kappos
1
,
Bar‐Or
2
,
Cree
3
et al.
2018
The Lancet
958
10
757
2
2
Get access via publisher
Add to collection
Cite
Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging
Dal‐Bianco
1
,
Grabner
2
,
Kronnerwetter
3
et al.
2016
Acta Neuropathol
Abstract
Show
490
54
643
6
Get access via publisher
Add to collection
Cite
Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI
Dal‐Bianco
1
,
Grabner
2
,
Kronnerwetter
3
et al.
2021
Abstract
Show
245
31
291
4
Get access via publisher
Add to collection
Cite
Electrocardiographic Changes at the Onset of Epileptic Seizures
Leutmezer
1
,
Schernthaner
2
,
Lurger
3
et al.
2003
Epilepsia
Abstract
Show
307
18
284
2
Get access via publisher
Add to collection
Cite
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Wiendl
1
,
Gold
2
,
Berger
3
et al.
2021
Ther Adv Neurol Disord
Abstract
Show
206
3
183
1
Get access via publisher
Add to collection
Cite
Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients
Lehrner
1
,
Kalchmayr
2
,
Serles
3
et al.
1999
Seizure
Abstract
Show
197
7
85
2
Get access via publisher
Add to collection
Cite
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study
Bar‐Or
1
,
Wiendl
2
,
Montalbán
3
et al.
2021
Mult Scler
Abstract
Show
71
3
91
0
Get access via publisher
Add to collection
Cite
Macular ganglion cell–inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis
Bsteh
1
,
Berek
2
,
Hegen
3
et al.
2020
Mult Scler
Abstract
Show
69
8
85
1
Get access via publisher
Add to collection
Cite
1
2
3
4
5